Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Anaptysbio Inc (NQ: ANAB )

18.72 +0.24 (+1.30%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 159,088
Open 18.55
Bid (Size) 17.68 (1)
Ask (Size) 19.25 (2)
Prev. Close 18.48
Today's Range 18.05 - 18.80
52wk Range 18.03 - 32.44
Shares Outstanding 27,433,359
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AnaptysBio Announces Participation in Upcoming Investor Conferences
From AnaptysBio, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For May 22, 2023
 
Via Benzinga

Performance

YTD
-35.93%
-35.93%
1 Month
-12.93%
-12.93%
3 Month
-21.44%
-21.44%
6 Month
-31.45%
-31.45%
1 Year
+0.05%
+0.05%

More News

Read More
AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update
From AnaptysBio, Inc.
Via GlobeNewswire
HC Wainwright Sees 40% Upside For This Once Battered Stock With Pipeline Turnaround
Via Benzinga
AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP)
From AnaptysBio, Inc.
Via GlobeNewswire
AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors
From AnaptysBio, Inc.
Via GlobeNewswire
GSK Unveils Detailed Phase 3 Data For Jemperli In Frontline Endometrial Cancer Patients
Via Benzinga
AnaptysBio- and GSK-partnered immuno-oncology agent Jemperli (dostarlimab-gxly) plus chemotherapy demonstrates statistically significant and clinically meaningful improvement in progression-free survival for the treatment of primary advanced or recurrent
From AnaptysBio, Inc.
Via GlobeNewswire
AnaptysBio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
AnaptysBio to Participate at the Cowen and Company 43rd Annual Health Care Conference
From AnaptysBio, Inc.
Via GlobeNewswire
AnaptysBio Announces Stock Repurchase Plan
From AnaptysBio, Inc.
Via GlobeNewswire
Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Greenbrier, Fate Therapeutics, AnaptysBio And Some Other Big Stocks Moving Lower On Friday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies
From AnaptysBio, Inc.
Via GlobeNewswire
AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer
From AnaptysBio, Inc.
Via GlobeNewswire
AnaptysBio to Participate at the Piper Sandler 34th Annual Healthcare Conference
From AnaptysBio, Inc.
Via GlobeNewswire
Expert Ratings for AnaptysBio
Via Benzinga
AnaptysBio to Participate in Upcoming November Investor Conferences
From AnaptysBio, Inc.
Via GlobeNewswire
AnaptysBio Announces Third Quarter 2022 Financial Results and Provides Pipeline Update
From AnaptysBio, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
Via Benzinga
AnaptysBio / GSK-Partnered Immuno-Oncology Agent Meets Primary Goal In Lung Cancer Trial
Via Benzinga
AnaptysBio and GSK-partnered immuno-oncology agents JEMPERLI (dostarlimab-gxly) and cobolimab show positive progress in two separate non-small cell lung cancer trials
From AnaptysBio, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.